Healthy volunteers test new injection method for eczema drug

NCT ID NCT06268860

Completed Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested how the body absorbs rocatinlimab, a potential eczema treatment, when given through a vial versus a prefilled syringe. 240 healthy adults received a single dose to compare the two methods. The goal was to see if the syringe works as well as the vial, not to treat any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Fortrea Clinical Research Unit - Dallas

Dallas, Texas, 75247-4903, United States
Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117-5116, United States
Fortrea Clinical Research Unit Inc. - Madison

Madison, Wisconsin, 53704-2526, United States
Fortrea Clinical Research Unit Limited - Leeds

Leeds, LDS, LS2 9LH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.